Article

Oncology’s transitional generation: charting the way to integrated, efficient, and cost-effective delivery systems


 

As we move into a new year, it is worth reflecting on the substantial advances in oncology during 2011. It was a remarkable year, with progress in basic as well as translational research that yielded major new therapies in breast cancer, melanoma, prostate cancer, leukemias, and several other cancers and blood diseases. We saw progress in prevention for breast cancer, in improving cure rates in early-stage diseases, and in prolonging life in several advanced-stage cancers. The publication of data suggesting targeted immunotherapy as a possible cure for patients with advanced refractory chronic lymphocytic leukemia (CLL) should encourage us to prioritize referrals to and participation in clinical trials...

*For a PDF of the full article, click in the link to the left of this introduction.

Recommended Reading

House OKs 2-Year Physician Fee Fix
MDedge Hematology and Oncology
FDA Issues New Rule on Drug Shortages
MDedge Hematology and Oncology
Senate Passes Short-Term SGR Fix
MDedge Hematology and Oncology
Enrollment Up for Medicare Advantage Plans
MDedge Hematology and Oncology
AMA Debates Role of Patient Navigators
MDedge Hematology and Oncology
CMS Prepares to Hold Medicare Payments
MDedge Hematology and Oncology
Obama Signs Short-Term SGR Fix; Doctors Still Angry
MDedge Hematology and Oncology
Texas Tort Reform: More Complaints, Lower Costs
MDedge Hematology and Oncology
Commentary - Health Care Armageddon Has Arrived
MDedge Hematology and Oncology
FDA Issues One REMS for All Transmucosal Fentanyl
MDedge Hematology and Oncology